Bristol Myers wins accelerated approval for another blood cancer for blockbuster Breyanzi

Just two months after earning another approval for its blockbuster blood cancer drug Breyanzi, Bristol Myers Squibb can add an accelerated approval to the list, this time in the third-line setting for adult patients with relapsed or refractory follicular lymphoma.

The FDA approved the single-dose, one-time CAR-T therapy for the…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks